Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | POLB | P06746 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | CDC25B | P30305 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | CDC25A | P30304 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | MAP2K7 | O14733 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571557 | 1.00 | MAPT (1.00) | MAPTALDH1A1POLBKDM4ESMN1; SMN2 | |
| Benzoquinone SCHEMBL6130614 | 0.91 | MAPT (0.82) | MAPTALDH1A1POLBKDM4ESMN1; SMN2 | |
| SCHEMBL30002742 | 0.87 | CDC25B (1.00) | MAPTALDH1A1POLBKDM4ESMN1; SMN2 | |
| SCHEMBL3414838 | 0.87 | CDC25B (1.00) | MAPTALDH1A1POLBKDM4ESMN1; SMN2 | |
| SCHEMBL16138414 | 0.87 | MAPT (0.75) | MAPTALDH1A1POLBKDM4ESMN1; SMN2 | |
| SCHEMBL10901421 | 0.87 | MAPT (0.75) | MAPTALDH1A1POLBKDM4ESMN1; SMN2 | |
| SCHEMBL8285443 | 0.84 | MAPT (0.71) | MAPTALDH1A1POLBKDM4ESMN1; SMN2 | |
| SCHEMBL9562528 | 0.84 | MAPT (0.71) | MAPTALDH1A1POLBKDM4ESMN1; SMN2 | |
| SCHEMBL1436501 | 0.84 | MAPT (0.71) | MAPTALDH1A1POLBKDM4ESMN1; SMN2 | |
| SCHEMBL14662804 | 0.84 | MAPT (0.71) | MAPTALDH1A1POLBKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119606931-A | Application of 2, 3-dimethoxy-1, 4-naphthoquinone in preparation of inducer for inducing death of tumor cell iron and medicine for treating gastric cancer | 济南市中心医院 | 2025-03-14 | — | — | CN | claimed |
| WO-2023246464-A1 | USE OF CRYPTOTANSHINONE SUBSTANCE AND COMBINED COMPOSITION THEREOF | 澳门大学 | 2023-12-28 | — | — | WO | claimed |
| EP-4218819-A2 | COMBINATION THERAPY BASED ON PD-1 SIGNAL INHIBITORS | Kyoto University (JP) | 2023-08-02 | — | — | EP | claimed |
| WO-2023068423-A1 | COMPLEX ANTICANCER DRUG COMPOSITION USING PHOTOREACTIVITY AND PREPARATION METHOD THEREFOR | 닥터아이앤비(주) | 2023-04-27 | — | — | WO | claimed |
| CN-115054608-A | Application of cryptotanshinone substances and combination composition thereof | 澳门大学 | 2022-09-16 | — | — | CN | claimed |
| CN-114601930-A | Combination therapy of PD-1 signaling inhibitors | 国立大学法人京都大学 | 2022-06-10 | — | — | CN | claimed |
| CN-114404595-A | Combination therapy of PD-1 signaling inhibitors | 国立大学法人京都大学 | 2022-04-29 | — | — | CN | claimed |
| US-20260083701-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR TREATMENT OF INFLAMMATORY CONDITIONS | ODDITY LABS LLC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4688151-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR TREATMENT OF INFLAMMATORY CONDITIONS | Oddity Labs, LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4635959-A1 | NOVEL CRYSTALLINE FORM OF MAGNESIUM-SERINATE AND METHOD FOR PRODUCING SAME | Astrogen, Inc. (KR) | 2025-10-22 | — | — | EP | disclosed |
| US-20250288542-A1 | METHODS AND COMPOSITIONS TO TREAT AND PREVENT VIRAL INFECTIONS AND ACUTE RESPIRATORY DISTRESS SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-09-18 | — | — | US | disclosed |
| WO-2025110267-A1 | L-SERINE HAVING REDUCED HEAVY METAL CONTENT, PHARMACEUTICAL COMPOSITION THEREOF, METHOD FOR PREPARING SAME, AND USE THEREOF | 주식회사 아스트로젠 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025110614-A1 | L-SERINE HAVING REDUCED HEAVY METAL AMOUNT, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 주식회사 아스트로젠 | 2025-05-30 | — | — | WO | disclosed |
| US-20220362260-A1 | METHODS OF TREATING LIPEDEMA INCLUDING AKR1C1 AS A THERAPEUTIC TARGET | MAGI EUREGIO SCS (IT) | 2022-11-17 | — | — | US | disclosed |
| CN-110891980-B | Radical polymerization control agent and radical polymerization control method | 川崎化成工业株式会社 | 2022-09-30 | — | — | CN | disclosed |
| CN-115054608-A | Application of cryptotanshinone substances and combination composition thereof | 澳门大学 | 2022-09-16 | — | — | CN | disclosed |
| EP-2858974-B9 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORP (JP) | 2022-07-20 | — | — | EP | disclosed |
| CN-114601930-A | Combination therapy of PD-1 signaling inhibitors | 国立大学法人京都大学 | 2022-06-10 | — | — | CN | disclosed |
| CN-114404595-A | Combination therapy of PD-1 signaling inhibitors | 国立大学法人京都大学 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022072745-A1 | METHODS AND COMPOSITIONS TO TREAT AND PREVENT VIRAL INFECTIONS AND ACUTE RESPIRATORY DISTRESS SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083701-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR TREATMENT OF INFLAMMATORY CONDITIONS | IL23R, NR3C2, HCRTR2 | MAPT 3377/4885ALDH1A1 2818/4885POLB 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.